SBME Introduces Their New Executive Advisory Committee

The School of Biomedical Engineering has a brand new Executive Advisory Committee (EAC)! Their three-year term will begin March 1, 2021. Comprised of established scientific leaders in the field of biomedical engineering, and representing prominent international institutions, SBME’s EAC provides expert, third-party, evidenced-based input on strategic and operational aspects of the School. They help the school grow, adapt and move…
Read More
Canada is home to significant scientific expertise and research tackling COVID-19, though one expert says long-standing hurdles make it difficult for the country to punch above its weight in the global fight against the virus. Among the standout contributions is a Vancouver biotech company that’s producing a key component of several vaccines, but a University of British Columbia professor says…
Read More
Whole genome sequencing allows for the identification of novel genomic alterations that are not detected by standard clinical techniques. In some cases, identification of these features can reveal therapeutic options for patients with otherwise untreatable cancers. In a new study published in the Wiley journal Clinical Case Reports, researchers presented a case in which whole genome analysis unveiled a drug target…
Read More
The rapid emergence and propagation of the novel coronavirus SARS-CoV-2 has prompted collaborations among scientist from diverse fields of research, all looking to understand and hopefully predict the course that COVID-19 is taking. One of these teams is composed of the Centre for Blood Research’s (CBR) own Dr. Natalie Strynadka, in addition to Dr. Robert Brunham, head of the Vaccine Research Laboratory…
Read More
Researchers in B.C. are working on developing a breath test for COVID-19 that if successful, could provide results in less than one minute. The test could theoretically be rolled out in the community — at airports, schools, arenas and other venues, said Dr. Renelle Myers, an interventional respirologist at Vancouver General Hospital and B.C. Cancer Research Centre who is leading…
Read More
With an average of 73 Canadians being diagnosed with colorectal cancer every day, the disease is the second leading cause of cancer death in men and the third in women. Reducing colorectal cancer fatalities will require better knowledge of the disease and the development of novel treatment and screening strategies—endeavors that are currently being undertaken by GSC Senior Scientist Dr.…
Read More
Working with colleagues and patients in the urology space at the University of British Columbia, I encountered indwelling device-associated infections as a significant issue. It made an impact. There is a real need for a solution that’s actually working. In 2008, I met Purus Innovations Co-founder Jayachandran (Jay) Kizhakkedathu during my postdoc in urologic sciences. Jay is a professor in…
Read More

The CBR Celebrates #WomenInScience Day 2021

February 11 is recognized by the United Nations as the International Day of Women and Girls in Science, which aims to spotlight the contributions of women in STEM and encourage full and equal access to participation in science, technology, and innovation for women and girls. This year, we chatted with several women researchers in the CBR community to learn more about…
Read More
AbCellera announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021. As CTO, Dr. Falconer will lead AbCellera’s long-term strategy in the development, aggregation, and integration of technologies that improve the speed and success of therapeutic antibody discovery from target to investigational new drug application submission. “Dr. Falconer is an accomplished and…
Read More
Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of…
Read More